XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive (loss) income
Beginning balance (in shares) at Dec. 31, 2020     43,637,000          
Balance at beginning of period at Dec. 31, 2020 $ 619,688   $ 44 $ 873,201   $ (253,875)   $ 318
Increase (Decrease) in Stockholders' Equity                
Exercise of stock options (in shares)     479,000          
Exercise of stock options 16,022     16,022        
Vested restricted stock units (in shares)     290,000          
Vested restricted stock units 0              
Common stock issued under employee stock purchase plan (in shares)     31,000          
Common stock issued under employee stock purchase plan 1,574     1,574        
Stock-based compensation 20,571     20,571        
Other comprehensive income (loss) (137)             (137)
Net income 29,450         29,450    
Ending balance (in shares) at Jun. 30, 2021     44,437,000          
Balance at end of period at Jun. 30, 2021 687,168   $ 44 911,368   (224,425)   181
Beginning balance (in shares) at Dec. 31, 2020     43,637,000          
Balance at beginning of period at Dec. 31, 2020 619,688   $ 44 873,201   (253,875)   318
Ending balance (in shares) at Dec. 31, 2021     44,734,000          
Balance at end of period at Dec. 31, 2021 $ 730,408 $ (49,233) $ 45 942,091 $ (96,468) (211,895) $ 47,235 167
Increase (Decrease) in Stockholders' Equity                
Reclassification of the equity component of convertible senior notes to liabilities upon adoption of Accounting Standards Update 2020-06 (Note 2) Accounting Standards Update 2020-06 Retrospective [Member]              
Beginning balance (in shares) at Mar. 31, 2021     43,958,000          
Balance at beginning of period at Mar. 31, 2021 $ 650,818   $ 44 894,108   (243,506)   172
Increase (Decrease) in Stockholders' Equity                
Exercise of stock options (in shares)     162,000          
Exercise of stock options 5,225     5,225        
Vested restricted stock units (in shares)     286,000          
Vested restricted stock units 0              
Common stock issued under employee stock purchase plan (in shares)     31,000          
Common stock issued under employee stock purchase plan 1,574     1,574        
Stock-based compensation 10,461     10,461        
Other comprehensive income (loss) 9             9
Net income 19,081         19,081    
Ending balance (in shares) at Jun. 30, 2021     44,437,000          
Balance at end of period at Jun. 30, 2021 687,168   $ 44 911,368   (224,425)   181
Beginning balance (in shares) at Dec. 31, 2021     44,734,000          
Balance at beginning of period at Dec. 31, 2021 $ 730,408 $ (49,233) $ 45 942,091 $ (96,468) (211,895) $ 47,235 167
Increase (Decrease) in Stockholders' Equity                
Exercise of stock options (in shares) 630,413   630,000          
Exercise of stock options $ 21,935   $ 1 21,934        
Vested restricted stock units (in shares)     299,000          
Vested restricted stock units $ 0              
Common stock issued under employee stock purchase plan (in shares) 36,729   37,000          
Common stock issued under employee stock purchase plan $ 1,821     1,821        
Stock-based compensation 22,733     22,733        
Issuance of common stock upon conversion of 2022 convertible senior notes (Note 9) (in shares)     102,000          
Issuance of common stock upon conversion of 2022 convertible senior notes (Note 9) 3,040     3,040        
Other comprehensive income (loss) (772)             (772)
Net income 26,704         26,704    
Ending balance (in shares) at Jun. 30, 2022     45,802,000          
Balance at end of period at Jun. 30, 2022 756,636   $ 46 895,151   (137,956)   (605)
Beginning balance (in shares) at Mar. 31, 2022     45,064,000          
Balance at beginning of period at Mar. 31, 2022 709,576   $ 45 867,890   (157,832)   (527)
Increase (Decrease) in Stockholders' Equity                
Exercise of stock options (in shares)     307,000          
Exercise of stock options 10,857   $ 1 10,856        
Vested restricted stock units (in shares)     292,000          
Vested restricted stock units 0              
Common stock issued under employee stock purchase plan (in shares)     37,000          
Common stock issued under employee stock purchase plan 1,821     1,821        
Stock-based compensation 11,544     11,544        
Issuance of common stock upon conversion of 2022 convertible senior notes (Note 9) (in shares)     102,000          
Issuance of common stock upon conversion of 2022 convertible senior notes (Note 9) 3,040     3,040        
Other comprehensive income (loss) (78)             (78)
Net income 19,876         19,876    
Ending balance (in shares) at Jun. 30, 2022     45,802,000          
Balance at end of period at Jun. 30, 2022 $ 756,636   $ 46 $ 895,151   $ (137,956)   $ (605)